Neoleukin Therapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. The net income raised on -$56,017,000 over the previous period. Total operating expenses were $59,097,000.
Profit Margin
| 2013 | 0 | -9.29M | |
|---|---|---|---|
| 2014 | 0 | -23.82M | |
| 2015 | 0 | -21.86M | |
| 2016 | 0 | -37.00M | |
| 2017 | 0 | -50.18M | |
| 2018 | 25M | -31.58M | -126.34% |
| 2019 | 0 | -69.43M | |
| 2020 | 451K | -24.95M | -5533.48% |
| 2021 | 6K | -58.41M | -973583.33% |
| 2022 | 0 | -56.01M |
NLTX Income Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue | 0 | 6K | 451K | 0 | 25M | 0 | 0 | 0 | 0 | 0 |
Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Gross profit | 0 | 6K | 451K | 0 | 25M | 0 | 0 | 0 | 0 | 0 |
Operating exp. | ||||||||||
Research and development | 41.12M | 39.16M | 24.34M | 4.41M | 41.78M | 36.26M | 28.38M | 15.79M | 18.07M | 7.53M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 59.09M | 60.69M | 41.55M | 23.24M | 57.62M | 51.11M | 37.64M | 21.34M | 22.37M | 9.37M |
Operating income | -59.09M | -60.69M | -33.72M | -70.95M | -32.62M | -51.11M | -37.64M | -21.34M | -23.56M | -9.37M |
Other income (expenses), net | 1.54M | 6K | 7.82M | 1.51M | -520K | 936K | 25K | -520K | 487.59K | 657.84K |
Income before tax | -57.55M | -60.69M | -33.27M | -69.44M | -31.58M | -50.18M | -37.00M | -21.86M | -24.02M | -8.73M |
Income tax expense | -1.54M | -2.27M | -8.32M | -7K | -1.04M | -940K | -644K | 421K | -222 | -5.04K |
Net income | -56.01M | -58.41M | -24.95M | -69.43M | -31.58M | -50.18M | -37.00M | -21.86M | -23.82M | -9.29M |
Earnings per share | ||||||||||
Basic EPS | -1.01 | -1.06 | -0.48 | -2.57 | -1.34 | -2.14 | -1.96 | -1.73 | -2.75 | -0.93 |
Diluted EPS | -1.01 | -1.06 | -0.48 | -2.57 | -1.34 | -2.14 | -1.96 | -1.73 | -2.75 | -0.93 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |